Research Topics
Genomes and GenesSpecies | Carlo PalmieriSummaryAffiliation: Imperial College Country: UK Publications
| Collaborators
|
Detail Information
Publications
A randomized feasibility study of docetaxel versus vinorelbine in advanced breast cancerCarlo Palmieri
M B B S, F R C P, Department of Medical Oncology, Imperial College NHS Healthcare Trust, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK
Oncologist 17:1429-e47. 2012....- Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBPδ) CpG island in breast cancer is associated with metastatic relapseC Palmieri
Cancer Research UK Laboratories, Imperial Centre for Translational and Experimental Medicine, Division of Cancer, Imperial College London, Du Cane Road, London W12 0NN, UK
Br J Cancer 107:732-8. 2012..It has properties consistent with a tumour suppressor; however, other data suggest that CEBPδ may be involved in the metastatic process... - Methylation of the calcium channel regulatory subunit α2δ-3 (CACNA2D3) predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomasC Palmieri
Cancer Research UK Laboratories, Imperial Centre for Translational and Experimental Medicine, Division of Cancer, Imperial College London, Du Cane Road, London W12 0NN, UK
Br J Cancer 107:375-81. 2012..Calcium ion channels are key in controlling the intracellular calcium, and little is known about their role in human cancer... 
Ethnicity and breast cancer researchCarlo Palmieri
Cancer Research UK Laboratories, Department of Cancer Medicine, Imperial College, London W12 0NN, UK
Lancet 372:188-9. 2008
Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab eraCarlo Palmieri
Cancer Research UK Laboratories, Division of Cancer, Imperial College London, UK
Clin Breast Cancer 11:93-102. 2011..This study explores the use and nonuse of AT in early breast cancer, as well as the efficacy in a neoadjuvant and adjuvant population, within a routine clinical setting...- Serum 25-hydroxyvitamin D levels in early and advanced breast cancerC Palmieri
Cancer Research UK Laboratories, Department of Cancer Medicine, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
J Clin Pathol 59:1334-6. 2006..Serum levels of 1,25(OH)(2)D are higher in normal women than in patients with primary breast cancer... - Placental-site trophoblastic tumour: an unusual presentation with bilateral ovarian involvementCarlo Palmieri
Department of Cancer Medicine, Charing Cross Hospital, London, UK
Lancet Oncol 6:59-61. 2005 - Rechallenging with anthracyclines and taxanes in metastatic breast cancerCarlo Palmieri
Cancer Research UK Laboratories, Department of Oncology, MRC Cyclotron Building, Faculty of Medicine, Imperial College London, Du Cane Road, London W12 ONN, UK
Nat Rev Clin Oncol 7:561-74. 2010..This Review examines the evidence for rechallenging with both anthracyclines and taxanes, and highlights the issues that need to be examined in the context of future clinical trials... - Managing malignant disease in patients with porphyriaC Palmieri
Department of Cancer Medicine, Faculty of Medicine, Imperial College London, UK
QJM 97:115-26. 2004..We briefly review the biochemical basis, clinical features and current management of porphyria in cancer patients... - Irosustat: a first-generation steroid sulfatase inhibitor in breast cancerCarlo Palmieri
Cancer Research UK Laboratories, Division of Cancer, Imperial College, Du Cane Road, London W12 0NN, UK
Expert Rev Anticancer Ther 11:179-83. 2011.... - Reproducibility of [11C]choline-positron emission tomography and effect of trastuzumabLaura M Kenny
Department of Cancer Medicine, Imperial College, London, UK
Clin Cancer Res 16:4236-45. 2010..This study sought to evaluate the reproducibility of [(11)C]choline-positron emission tomography and the effect of trastuzumab in breast cancer... - Biological basis of [¹¹C]choline-positron emission tomography in patients with breast cancer: comparison with [¹⁸F]fluorothymidine positron emission tomographyKaiyumars B Contractor
Department of Oncology, Imperial College London, London, UK
Nucl Med Commun 32:997-1004. 2011..Furthermore, we evaluated CHKα and the Ki67-labelling index (LIKi67) in tumour biopsies... - Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomographyLaura M Kenny
Department of Oncology, Imperial College London, London, United Kingdom
Clin Cancer Res 15:6649-57. 2009..In this study, we assessed for the first time the altered pharmacokinetics of FLT in patients following administration of capecitabine, a drug whose mode of action has been reported to include TS inhibition... - Human epidermal growth factor receptor 2-positive breast cancer relapsing post-adjuvant trastuzumab: pattern of recurrence, treatment and outcomeJonathan Krell
Department of Medical Oncology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK
Clin Breast Cancer 11:153-60. 2011..The purpose of this study is to evaluate the response to and benefit of first-line metastatic treatment (including re-exposure to trastuzumab) for patients relapsing after exposure to adjuvant trastuzumab (AT)... - [11C]choline positron emission tomography in estrogen receptor-positive breast cancerKaiyumars B Contractor
Department of Oncology, Imperial College, London, United Kingdom
Clin Cancer Res 15:5503-10. 2009.... - Fulvestrant in advanced breast cancer following tamoxifen and aromatase inhibition: a single center experienceJayson Wang
Department of Cancer Medicine, Imperial College London, Charing Cross Hospital, London, UK
Breast J 15:247-53. 2009..This data suggest fulvestrant is well tolerated and is a useful treatment option in patients with advanced breast cancer who progress on prior endocrine treatment... - Imaging of cellular proliferation in liver metastasis by [18F]fluorothymidine positron emission tomography: effect of therapyKaiyumars Contractor
Faculty of Medicine, Imperial College London, London, UK
Phys Med Biol 57:3419-33. 2012..FLT-PET and FLT-PET(KSF) detected changes in proliferation in liver metastases... - Role of fulvestrant in the management of postmenopausal breast cancerJonathan Krell
Department of Surgery and Cancer, MRC Cyclotron Building, Faculty of Medicine, Imperial College London, Du Cane Road, London, W12 ONN, UK
Expert Rev Anticancer Ther 11:1641-52. 2011..Fulvestrant is a well-tolerated drug and its toxicities will also be reviewed. The optimal position of fulvestrant in sequential endocrine therapy has yet to be defined... - FoxM1 is a downstream target and marker of HER2 overexpression in breast cancerRichard E Francis
Cancer Research UK Labs, Department of Oncology, Imperial College London, Hammersmith Hospital Campus, London W12 0NN, UK
Int J Oncol 35:57-68. 2009..Our results indicate that the HER2 receptor regulates the expression of the FoxM1 transcription factor, which has a role in breast cancer development... - TGFβ1-Endo180-dependent collagen deposition is dysregulated at the tumour-stromal interface in bone metastasisMatthew P Caley
Department of Surgery and Cancer, Imperial College London, UK
J Pathol 226:775-83. 2012..The findings of this study provide a rationale for targeting collagen remodelling by Endo180 in bone metastases and other collagen matrix pathologies... - Breast cancer metastasizing to the tonguePratap Neelakantan
Department of Medical Oncology, Charing Cross Hospital, London, UK
Can J Surg 51:E63-4. 2008 - Voltage-gated sodium channel expression and potentiation of human breast cancer metastasisScott P Fraser
Neuroscience Solutions to Cancer Research Group, Department of Biological Sciences, Imperial College London, UK
Clin Cancer Res 11:5381-9. 2005..The purpose of this study was to investigate voltage-gated Na(+) channel (VGSC) expression and its possible role in human breast cancer... - Value of whole body 18FDG-PET to identify the active site of gestational trophoblastic neoplasiaTony Dhillon
Department of Medical Oncology, Charing Cross Hospital Campus of Imperial College, Fulham Palace Road, London W6 8RF, UK
J Reprod Med 51:879-87. 2006..However, careful evaluation in combination with other imaging modalities is required to reduce the risk of false positive and negative results... - Placental site trophoblastic tumour arising from a partial hydatidiform moleCarlo Palmieri
Department of Cancer Medicine, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK
Lancet 366:688. 2005 - Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breastSean R McLean
Department of Medical Oncology, Charring Cross Hospital, London, UK
J Cutan Pathol 34:934-8. 2007..In addition, clinical response to FEC by metastatic DEA has not been previously documented, and this therapeutic regimen warrants further investigation... - A 2009 update on the treatment of patients with hormone receptor-positive breast cancerSusan J Cleator
Breast Unit, St Mary s Hospital, Imperial College Healthcare NHS Trust, United Kingdom
Clin Breast Cancer 9:S6-S17. 2009..Mechanisms of resistance to endocrine interventions and trials exploring strategies to overcome them will also be discussed... - Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancerS J Stanway
Imperial College London, London, UK
Anticancer Res 31:1367-72. 2011..In contrast, little is known about the effects of aromatase inhibitors or anti-estrogens on STS activity or serum androgen levels... - Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patientsLaura M Kenny
Department of Oncology, Imperial College Faculty of Medicine, Hammersmith Hospital, London, United Kingdom
J Nucl Med 49:879-86. 2008.... - Targeted histone deacetylase inhibition for cancer prevention and therapyCarlo Palmieri
Department of Cancer Medicine, 7th Floor MRC Cyclotron Building, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK
Prog Drug Res 63:147-81. 2005 - Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancerFlora Stavridi
Department of Medical Oncology, St George s Hospital, Blackshaw Road, London, SW18 0QT, UK
Expert Rev Anticancer Ther 8:1859-69. 2008..The favorable cardiac safety profile of NPLD may allow it to be combined with newer therapies, such as trastuzumab... - Management and outcome of healthy women with a persistently elevated beta-hCGCarlo Palmieri
Department of Medical Oncology, Charing Cross Hospital, Fulham Palace Road, London, UK
Gynecol Oncol 106:35-43. 2007..Here we report the United Kingdom experience of patients with an elevated beta-hCG of initial uncertain cause and provide a clinical algorithm for the management of such cases... - Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trialNicola M Neary
Department of Metabolic Medicine, Faculty of Medicine, Imperial College London, London, United Kingdom W12 0NN
J Clin Endocrinol Metab 89:2832-6. 2004..The stimulatory effects of ghrelin on food intake and meal appreciation seen in this preliminary study suggest that ghrelin could be an effective treatment for cancer anorexia and possibly for appetite loss in other patient groups... - Severe thrombocytopenia induced by a single infusion of trastuzumabOmi Parikh
Royal Preston Hospital, London, UK
Clin Breast Cancer 8:285-6. 2008..This case highlights a serious and potentially life-threatening complication with the use of single-agent trastuzumab... - Is the presence of small volume disease in the sentinel node an indication for axillary clearance?Darren K Patten
Department of Biosurgery and Surgical Oncology, St Mary s Hospital, Imperial College Healthcare NHS Trust, London, UK Department of Breast Surgery, Imperial College Healthcare NHS Trust, London, UK Electronic address
Breast 22:70-3. 2013..Given the fact that axillary lymphadenectomy is associated with a 5-25% risk of lymphoedema, we propose that a policy of close follow up should be adopted in these patients rather than axillary lymphadenectomy... - The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survivalCarlo Palmieri
Department of Cancer Medicine, Cancer Cell Biology Group, Cancer Research UK Laboratories, Imperial College London, Hammersmith Hospital, London, United Kingdom
Clin Cancer Res 10:2421-8. 2004..ER beta cx, a variant of ER beta, has a dominant-negative effect over ER alpha, and its expression thought to modulate response to endocrine treatment may represent a predictor of response to endocrine therapy... - Angiosarcoma of the breast following surgery and radiotherapy for breast cancerRachel Abbott
Guy s and St Thomas Hospitals NHS Trust, London, UK
Nat Clin Pract Oncol 5:727-36. 2008..Overall survival, however, remains poor... - Fibroblast growth factor 7, secreted by breast fibroblasts, is an interleukin-1beta-induced paracrine growth factor for human breast cellsC Palmieri
Cancer Research UK Laboratories, Department of Cancer Medicine, MRC Cyclotron Building, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
J Endocrinol 177:65-81. 2003..In summary, our findings suggest that FGF7 is a paracrine growth factor in the breast. FGF7 is produced by the breast stromal fibroblasts and has profound proliferative and morphogenic roles on both epithelial and myoepithelial cells... - Resolution of late-onset asthma following high-dose chemotherapyC Palmieri
Department of Medical Oncology, Charing Cross Hospital, Fulham Palace Road, London, UK
Bone Marrow Transplant 32:847-8. 2003..As far as the authors are aware this is the first reported case... - Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatmentM J Slade
1Department of Oncology, Imperial College, MRC Cyclotron Building, London W12 0NN, UK
Br J Cancer 100:160-6. 2009.... - Estrogen receptor beta in breast cancerC Palmieri
Department of Cancer Medicine, Cancer Cell Biology Group, Cancer Research Campaign Laboratories, Imperial College School of Medicine, Hammersmith Campus, Du Cane Road, London W12 ONN, UK
Endocr Relat Cancer 9:1-13. 2002.... - Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancerW Heller
Department of Medical Oncology, Cancer Research UK Laboratories, Faculty of Medicine, Imperial College London, London W6 8RF, UK
Oncol Rep 17:253-9. 2007.... - Therapeutic monoclonal antibodies in oncologyAdam P Levene
Department of Cardiology, Leeds General Infirmary, Leeds LS1 3EX, UK
J R Soc Med 98:146-52. 2005 - Palifermin and chemotherapy-induced oral mucositisCarlo Palmieri
N Engl J Med 352:1264-5; author reply 1264-5. 2005 - Gene-expression profiling and identification of patients at high risk of breast cancerCarlo Palmieri
Lancet 360:173; author reply 174. 2002